Home /Biblio

Biblio

Found 2554 results
Author [ Keyword(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
*Brachytherapy Combined Modality Therapy Endometrial Neoplasms/*radiotherapy/surgery Female Humans Hysterectomy Neoplasm Staging *Physician's Practice Patterns Radiation Oncology/*standards Radiotherapy
W. Small, du Bois, A., Bhatnagar, S., Reed, N. Simon, Pignata, S., Potter, R., Randall, M., Mirza, M., Trimble, E. L., Gaffney, D. K., and InterGroup, G. Cancer, “Practice patterns of radiotherapy in endometrial cancer among member groups of the Gynecologic Cancer Intergroup”, Int J Gynecol Cancer, vol. 19, pp. 395-9, 2009.
*Clinical Trials as Topic Endometrial Neoplasms/*therapy Female Humans *Translational Medical Research
C. L. Creutzberg, Kitchener, H. C., Birrer, M. J., Landoni, F., Lu, K. H., Powell, M., Aghajanian, C., Edmondson, R., Goodfellow, P. J., Quinn, M., Salvesen, H. B., Thomas, G., and Meeting, G. C. I. G. Endometria, “Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era”, Int J Gynecol Cancer, vol. 23, pp. 1528-34, 2013.
*Ethics
I. B. Vergote, “Organization and ethical aspects of randomized trials in gynecologic oncology”, Verh K Acad Geneeskd Belg, vol. 62, pp. 385-95; discussion 395-8, 2000.
20th Century History
J. B. Vermorken, Åvall-Lundqvist, E., Pfisterer, J., Bacon, M., ,, -OVAR, A. G. O., ,, -GCC, E. O. R. T. C., ,, ,, ,, ,, ,, -CTG, N. C. I. C., -US, N. C. I., ,, ,, and , “The Gynecologic Cancer Intergroup (GCIG): History and current status”, Ann Oncol, vol. 16 Suppl 8, pp. viii39-viii42, 2005.
21st Century Humans International Cooperation/history Medical Oncology/*organization & administration
J. B. Vermorken, Åvall-Lundqvist, E., Pfisterer, J., Bacon, M., ,, -OVAR, A. G. O., ,, -GCC, E. O. R. T. C., ,, ,, ,, ,, ,, -CTG, N. C. I. C., -US, N. C. I., ,, ,, and , “The Gynecologic Cancer Intergroup (GCIG): History and current status”, Ann Oncol, vol. 16 Suppl 8, pp. viii39-viii42, 2005.
80 and over Algorithms Chemotherapy
A. Fagotti, Fanfani, F., Vizzielli, G., Gallotta, V., Ercoli, A., Paglia, A., Costantini, B., Vigliotta, M., Scambia, G., and Ferrandina, G., “Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery?”, Gynecol Oncol, vol. 116, pp. 72-7, 2010.
80 and over Alopecia/chemically induced Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use Cisplatin/administration & dosage/adverse effects Combined Modality Therapy Cross-Over Studies Cyclophosphamide/administration & dosag
M. J. Piccart, Bertelsen, K., James, K., Cassidy, J., Mangioni, C., Simonsen, E., Stuart, G. C. E., Kaye, S. B., Vergote, I. B., Blom, R., Grimshaw, R., Atkinson, R. J., Swenerton, K. D., Tropé, C. G., Nardi, M., Kaern, J., Tumolo, S., Timmers, P., Roy, J. - A., Lhoas, F., Lindvall, B., Bacon, M., Birt, A., Andersen, J. E., Zee, B., Paul, J., Baron, B., and Pecorelli, S., “Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results”, J Natl Cancer Inst, vol. 92, pp. 699-708, 2000.
80 and over Angiogenesis Inhibitors/adverse effects/therapeutic use Antibodies
G. Emile, Chauvenet, L., Tigaud, J. M., Chidiac, J., E. Lauraine, P., and Alexandre, J., “A clinical experience of single agent bevacizumab in relapsing ovarian cancer”, Gynecol Oncol, vol. 129, pp. 459-62, 2013.
80 and over Antimetabolites
G. Ferrandina, Ludovisi, M., Corrado, G., Carone, V., Petrillo, M., and Scambia, G., “Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer”, Gynecol Oncol, vol. 109, pp. 187-93, 2008.
80 and over Antineoplastic Agents/*administration & dosage Antineoplastic Agents
D. H. Moore, Blessing, J. A., McQuellon, R. P., Thaler, H. T., Cella, D., Benda, J., Miller, D. S., Olt, G., King, S., Boggess, J. F., and Rocereto, T. F., “Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study”, J Clin Oncol, vol. 22, pp. 3113-9, 2004.
80 and over Antineoplastic Agents/*therapeutic use Antineoplastic Combined Chemotherapy Protocols/therapeutic use Carboplatin/administration & dosage Carcinoma/*drug therapy/*pathology/surgery Chemotherapy
J. B. Trimbos, Vergote, I. B., Bolis, G., Vermorken, J. B., Mangioni, C., Madronal, C., Franchi, M., Tateo, S., Zanetta, G., Scarfone, G., Giurgea, L., Timmers, P., Coens, C., Pecorelli, S., Collaborators, E. O. R. T. C. - A. C. T. I. O. N., Research, E. Organisati, and Neoplasm, Tof Cancer-, “Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial”, J Natl Cancer Inst, vol. 95, pp. 113-25, 2003.
80 and over Antineoplastic Agents/*therapeutic use Antineoplastic Combined Chemotherapy Protocols/therapeutic use Carboplatin/administration & dosage Carcinoma/*drug therapy/pathology/surgery Chemotherapy
N. Colombo, Guthrie, D., Chiari, S., Parmar, M. K. B., Qian, W., Swart, A. Marie, Torri, V., Williams, C., Lissoni, A., Bonazzi, C., and Collaborators, I. Collaborat, “International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer”, J Natl Cancer Inst, vol. 95, pp. 125-32, 2003.
80 and over Antineoplastic Agents/administration & dosage/therapeutic use/toxicity Antineoplastic Agents
S. Pignata, Breda, E., Scambia, G., Pisano, C., Zagonel, V., Lorusso, D., Greggi, S., De Vivo, R., Ferrandina, G., Gallo, C., and Perrone, F., “A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study”, Crit Rev Oncol Hematol, vol. 66, pp. 229-36, 2008.
80 and over Antineoplastic Agents/pharmacology Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use Carboplatin/administration & dosage Cisplatin/pharmacology Deoxycytidine/administration & dosage/analogs & derivatives Disease
J. Pfisterer, Plante, M., Vergote, I. B., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G. C. E., Kimmig, R., Olbricht, S., Le, T., Emerich, J., Kuhn, W., Bentley, J., Jackisch, C., Luck, H. J., Rochon, J., Zimmermann, A. Hayden, Eisenhauer, E., -OVAR, A. G. O., -CTG, N. C. I. C., and -GCG, E. O. R. T. C., “Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG”, J Clin Oncol, vol. 24, pp. 4699-707, 2006.
80 and over Antineoplastic Agents/therapeutic use Female Gynecologic Surgical Procedures/*mortality Humans Middle Aged Neoplasm Recurrence
J. Pfisterer, Harter, P., Canzler, U., Richter, B., Jackisch, C., Hahmann, M., Hasenburg, A., Burges, A., Loibl, S., Gropp, M., Huober, J., Fink, D., du Bois, A., Committee, A. G. O. Ovarian, and Group, A. G. O. Ovarian Ca, “The role of surgery in recurrent ovarian cancer”, Int J Gynecol Cancer, vol. 15 Suppl 3, pp. 195-8, 2005.
80 and over Antineoplastic Combined Chemotherapy Protocols/*administration & dosage Carboplatin/administration & dosage Female Humans Middle Aged Ovarian Neoplasms/*drug therapy/pathology/surgery Paclitaxel/administration & dosage Survival Analysis
N. Katsumata, Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., Ochiai, K., Noda, K., and Group, J. Gynecologi, “Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial”, Lancet, vol. 374, pp. 1331-8, 2009.
80 and over Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects Carcinoma/drug therapy/pathology/surgery Cisplatin/*administration & dosage/adverse effects Combined Modality Therapy Drug Administration Schedule Female
D. Armstrong, Bundy, B. N., Wenzel, L. B., Huang, H., Baergen, R., Lele, S., Copeland, L., Walker, J. L., Burger, R. A., and Group, G. Oncology, “Intraperitoneal cisplatin and paclitaxel in ovarian cancer”, N Engl J Med, vol. 354, pp. 34-43, 2006.
80 and over Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Area Under Curve Carboplatin/*administration & dosage Cisplatin/*administration & dosage Combined Modality Therapy Female Humans Middle Aged Neoplasm Staging Ovarian Neoplasms/*d
R. F. Ozols, Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D. L., Burger, R. A., Mannel, R., DeGeest, K., Hartenbach, E. M., Baergen, R., and Group, G. Oncology, “Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study”, J Clin Oncol, vol. 21, pp. 3194-200, 2003.
80 and over Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carboplatin/administration & dosage Carcinoma
O. Tredan, Geay, J. - F., Touzet, S., Delva, R., Weber, B., Cretin, J., Provencal, J., Martin, J., Stefani, L., Pujade-Lauraine, E., Freyer, G., and Ovariens, Gd'Investig, “Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens”, Ann Oncol, vol. 18, pp. 256-62, 2007.
G. Freyer, Geay, J. - F., Touzet, S., Provencal, J., Weber, B., Jacquin, J. P., Ganem, G., Tubiana-Mathieu, N., Gisserot, O., and Pujade-Lauraine, E., “Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study”, Ann Oncol, vol. 16, pp. 1795-800, 2005.
80 and over Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carboplatin/administration & dosage Cisplatin/administration & dosage Female Humans Middle Aged Neoplasm Staging Ovarian Neoplasms/*drug therapy/pathology Paclitaxel/administrati
P. Wimberger, Lehmann, N., Kimmig, R., Burges, A., Meier, W., Hoppenau, B., du Bois, A., and -OVAR, A. G. O., “Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)”, Gynecol Oncol, vol. 100, pp. 300-7, 2006.
80 and over Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carboplatin/administration & dosage Female Humans Middle Aged Neoplasm Recurrence
A. Lortholary, Largillier, R., Weber, B., Gladieff, L., Alexandre, J., Durando, X., Slama, B., Dauba, J., Paraiso, D., Pujade-Lauraine, E., and France, G. I. N. E. C. O. Group, “Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)”, Ann Oncol, vol. 23, pp. 346-52, 2012.
80 and over Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma
C. W. Whitney, Sause, W., Bundy, B. N., Malfetano, J. H., Hannigan, E. V., Fowler, Jr., W. C., Clarke-Pearson, D. L., and Liao, S. Y., “Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study”, J Clin Oncol, vol. 17, pp. 1339-48, 1999.
80 and over Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/*therapeutic use Carboplatin/administration & dosage Disease-Free Survival Drug Administration Schedule Female France Germany Humans Middle Aged Ovarian Ne
J. Pfisterer, Weber, B., Reuss, A., Kimmig, R., du Bois, A., Wagner, U., Bourgeois, H., Meier, W., Costa, S., Blohmer, J. - U., Lortholary, A., Olbricht, S., Stähle, A., Jackisch, C., Hardy-Bessard, A. C., Möbus, V., Quaas, J., Richter, B., Schröder, W., Geay, J. - F., Luck, H. J., Kuhn, W., Meden, H., Nitz, U., Pujade-Lauraine, E., -OVAR, A. G. O., and , “Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO”, J Natl Cancer Inst, vol. 98, pp. 1036-45, 2006.
80 and over Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use Carboplatin/administration & dosage Disease Progression Disease-Free Survival Drug Administration Schedule Female France Humans Italy Kaplan-Meier Estimate Middle
S. Pignata, Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P. B., Cormio, G., Sorio, R., Cavazzini, M. G., Ferrandina, G., Breda, E., Murgia, V., Sacco, C., Cinieri, S., Salutari, V., Ricci, C., Pisano, C., Greggi, S., Lauria, R., Lorusso, D., Marchetti, C., Selvaggi, L., Signoriello, S., Piccirillo, M. C., Di Maio, M., Perrone, F., Cancer, M. Italian Tr, Sein, Gd'Investig, Oncology, M. Negri Gyne, Groups, E. Network of, and Investigators, G. Cancer Int, “Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial”, Lancet Oncol, vol. 15, pp. 396-405, 2014.

Pages